Archives: FAQs

This program provides patients with a unique mechanism to access bone marrow from our bank even if they cannot participate in the PRESERVE I clinical study. Bone marrow from our bank could provide benefits to the patient, including increased donor choice, decreased time to transplant, and optimal cell dose.

Adults with blood disorders that are unable to participate in the PRESERVE I clinical study may be eligible to participate in the HOPE Program. The patient’s doctor must determine that they are eligible for an allogeneic bone marrow transplant and that the potential benefits outweigh the potential risks. The determination on program eligibility is made by Ossium’s clinical staff based on information provided by the patient and their doctor.*

The HOPE Program provides an opportunity for patients with blood disorders to receive bone marrow from our bank when they can’t participate in the PRESERVE I clinical study.